Tags

  • Sorting

  • Filters

PFAS analysis in food: a robustness study in sensitivity and stability

The combination of per- and polyfluoroalkyl substances (PFAS) testing, trace-level regulatory requirements and complex MS applications can be intimidating. In a recent webinar, now available on demand, SCIEX PFAS expert Craig Butt demonstrated how the new SCIEX 7500+ system can help make PFAS testing easier.

Your success and voice go a long way!

At the heart of everything we do is ensuring that your workflows and team are empowered to achieve optimal results with your SCIEX instruments, software, consumables, and services. Every interaction with SCIEX is designed to support your success through the dedication...

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.

LC-MS system replacement: Are you ready?

Meeting deadlines in a bioanalysis laboratory can be a big challenge. Older, less sensitive and less reliable LC-MS systems make it even more difficult. Even the disruption caused by the installation and validation can be disconcerting and delay decisions. Does this sound familiar?

Overcoming uncertainty in your PFAS analysis

Overcoming uncertainty in your PFAS analysis

Just like gum on the bottom of a shoe, the existence of per- and poly-fluorinated alkyl substances (PFAS) in our environment is a sticky one. If you’re in the field of environmental testing, then you’re all too familiar with the threat these substances have on public health. While we have learned a lot about them over the years, there is still much more to understand. With the right detection methods, we can gather the information we need to empower us to make informed decisions on reducing the risks they impose.

6 Signs it’s time for a new vendor

6 Signs it’s time for a new vendor

A lab’s success depends on many factors from instrument quality to efficient operations, including being partnered with the right vendor. A vendor is more than just a supplier. They should provide you with a high-level quality of support in maximizing the lifespan and performance of your systems, reducing downtime, enhancing ROI and more. How do you know if you’re partnered with the right one? Here are six signs it might be time to find someone new.

Nitrosamines: Where are we now?

Nitrosamines: Where are we now?

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

FDA’s final rule on LDTs: what does it mean for clinical laboratories?

On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.

Guide decisions during cell line development with more information at the intact level

Guide decisions during cell line development with more information at the intact level

Monitoring product quality attributes (PQAs) throughout monoclonal antibody (mAb) development is vital to ensuring drug safety and efficacy. By adopting orthogonal analytical techniques and integrating new technologies that have the potential to provide more information, it is possible to improve product quality and manufacturing efficiency and make more informed decisions.

Back to the new basics: Part 1 | Making the leap from GC-MS to LC-MS

Back to the new basics: Part 1 | Making the leap from GC-MS to LC-MS

Producing accurate results quickly in a demanding environment is no easy feat for analytical scientists. What’s more, many of us are constantly questioning ourselves—I certainly am—about whether we are employing the best technique for the analysis at hand.

It’s an overwhelming thought, considering the wide range of tools that are available to choose from, each of which offers varying levels of capacity, sensitivity, selectivity, specificity and cost. How do you meet the unique needs of your organization without breaking the bank? I get it, and I’m not here to convince you it’s easy. My aim is to guide you through the process to help you make the right decision for you.

MRM method transfer from a SCIEX Triple Quad or QTRAP 6500+ system to the SCIEX 7500 system

MRM method transfer from a SCIEX Triple Quad or QTRAP 6500+ system to the SCIEX 7500 system

General recommendations when beginning method development Objective: The purpose of this document is to provide a quick reference for transferring MRM-based quantification methods from a SCIEX Triple Quad or QTRAP 6500+ system to a SCIEX 7500 system. While the best...

Identifying the unknown PFAS profile in firefighting foams/AFFF

Identifying the unknown PFAS profile in firefighting foams/AFFF

According to a recent study from Harvard University, the US EPA, and NIEHS, traditional targeted analysis techniques poorly characterize the PFAS composition of contemporary PFAS-based firefighting foams, know as aqueous film-forming foams (AFFF).  Using the EPA 533 PFAS drinking water method for the analyte list, the researchers found that targeted mass spectrometry methods accounted for <1% of organic fluorine content.  This is important because it demonstrates that targeted analysis methods miss nearly all the PFAS compounds in modern AFFF mixtures, thus underestimating the risk to human health and the environment.

Assess the performance of the Echo® MS system

High level method optimization considerations for Echo MS system

While an in-depth discussion of method development and optimization for the Echo® MS system is beyond the scope of a community post, here are some points to consider as part of the process: The maximum recommended ion spray voltage for prolonged electrode life is 5000...

Assess the performance of the Echo® MS system

Tips to maximize electrode lifetime for Echo MS system

While it’s easy to think of the Echo® MS system as an ultrafast LC system in front of the SCIEX Triple Quad 6500+ mass spectrometer, the system operates on fundamentally different principles. For this reason, it requires different routine maintenance to keep it...

Standard addition workflow – for quantification and calculating background levels

Standard addition workflow – for quantification and calculating background levels

The method of standard addition is a quantitative analysis approach used in situations where matrix effects from complex samples contributes to the analytical signal. This makes it impossible to compare the analytical signal between sample and standard using a...

How do I define the experimental design (the metadata) for my SWATH acquisition study within the OneOmics suite? What are the requirement for replicates?

How do I define the experimental design (the metadata) for my SWATH acquisition study within the OneOmics suite? What are the requirement for replicates?

In quantitative Omics research, the goal is to understand which analytes (protein or metabolite) are perturbed between experimental conditions; therefore we carefully design our studies to explore these questions. The algorithms used within the Assembler application...

Wordpress Social Share Plugin powered by Ultimatelysocial